CORBUS PHARMACEUTICALS HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.2 USD | -6.90% |
|
+5.14% | +648.34% |
Presenter SpeechTed Jenkins (Executives)Good morning, everyone. For those I've not met, my nam...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.
Calendar
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
48.55
USD
Average target price
71
USD
Spread / Average Target
+46.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +648.34% | 510M | |
| +8.63% | 115B | |
| +13.17% | 107B | |
| -12.76% | 22.31B | |
| -3.99% | 21.6B | |
| -7.19% | 18.23B | |
| -39.93% | 17.62B | |
| +6.67% | 14.26B | |
| +33.90% | 12.37B | |
| -28.60% | 8.28B |
- Stock Market
- Equities
- CRBP Stock
- News Corbus Pharmaceuticals Holdings, Inc.
- Transcript : Corbus Pharmaceuticals Holdings, Inc. - Special Call